Title:
FUSED RING COMPOUND
Document Type and Number:
WIPO Patent Application WO/2023/213297
Kind Code:
A1
Abstract:
The present invention relates to a fused ring compound; specifically, provided in the present invention is the use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof, in the preparation of a composition or a formulation for the prevention and/or treatment of tumours. The compound of the present invention has a significant and excellent precise therapeutic effect on tumours with low expression or no expression and low activity or no activity of mitochondrial permeability transition pores, low expression or no expression and low activity or no activity of peptidyl prolyl isomerase F, low expression or no expression of NNMT genes, high expression of DNA methylase, high expression of UHRF1, high methylation levels of NNMT gene nucleotide sites, and/or high methylation levels of DNA CpG sites in the NNMT gene region.
Inventors:
SHI YUFENG (CN)
MA WENJIANG (CN)
MA WENJIANG (CN)
Application Number:
PCT/CN2023/092263
Publication Date:
November 09, 2023
Filing Date:
May 05, 2023
Export Citation:
Assignee:
NANJING SHIJIANG MEDICINE TECH CO LTD (CN)
International Classes:
C07D455/03; A61K31/4375; A61P35/00; C12Q1/6886
Foreign References:
| CN114432307A | 2022-05-06 | |||
| CN102659777A | 2012-09-12 | |||
| CN101327214A | 2008-12-24 | |||
| CN105418601A | 2016-03-23 | |||
| CN106905313A | 2017-06-30 |
Attorney, Agent or Firm:
PANCHINA IP LAW OFFICE (CN)
Download PDF: